In Harvard Medical School in Ethics Quandary, Wilson (2009) discusses the ethical dilemma arising from the increased financial involvement of pharmaceutical industries in Harvard Medical School and its faculty. According to Wilson (2009) in the last decade Harvard Medical School has become the school that receives the most amount of independent funding from private companies, resulting to a grade of F from the American Medical Student Association rating how medical schools control money from the drug industry.
Similarly, a large number of its faculty has significant connections with pharmaceutical firms with its previous Dean being a board member for medical products company Baxter International. Wilson (2009) also reports that Harvard Medical School has no regulation that requires its teaching staff to report their affiliations of amounts they received due to their affiliations with private firms. According to Wazana (2003) the interaction between physicians and the pharmaceutical industry creates a conflict of interest.
Exposure to the promotional activities of pharmaceutical companies can influence the opinions of physicians (Goodman, 2003), which is the same sentiment expressed by Harvard Medical Students over the opinions expressed by professors receiving private funding (Wilson, 2009). However, another opinion, one supporting the relationship between Medical Schools and Pharmaceutical firms, has also been established among Harvard students (Wilson 2009). They argue that the financial support through private funding allows for continued research and development of new medicines.
Ultimately the issue here is whether the increased involvement of private firms in funding for Medical Schools and its faculty affects the behavior and practice of the faculty and ultimately what they teach their students. Wazana (2003) also points out that increasingly important to note is that if such influences affect professors, then the education received by future doctors may become tainted as well. Reference List Goodman, R. (2003). “Drug Company Sponsorship of Clinical Conferences: Commentary 1.
” Virtual Mentor. Retrieved April 9, 2009 from http://virtualmentor. ama-assn. org/2003/07/ccas1-0307. html Wazana, A. (2003). “Drug Company Sponsorship of Clinical Conferences: Commentary 2. ” Virtual Mentor. Retrieved April 9, 2009 from http://virtualmentor. ama-assn. org/2003/07/ccas1-0307. html Wilson, D. (2009, March 2). “Harvard Medical School in Ethics Quandary. ” The New York Times. Retrieved April 9, 2009 from http://www. nytimes. com/2009/03/03/business/03medschool. html